Categories: Health

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

 | Source: Keros Therapeutics, Inc.

LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate at the following healthcare conferences:

TD Cowen 45th Annual Healthcare Conference

Leerink Partners Global Healthcare Conference

For each presentation, an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of each event.

About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. One of Keros’ product candidates, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros’ second product candidate, KER-065, is being developed for the treatment of neuromuscular diseases. Keros’ most advanced product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis.

Investor Contact:
Justin Frantz
jfrantz@kerostx.com    

617-221-6042    

GlobeNews Wire

Recent Posts

MSI Announces the availability of RTX 50 series of laptops in India

MUMBAI, India, March 13, 2025 /PRNewswire/ -- MSI, the innovative computing manufacturer in gaming, creator,…

4 minutes ago

Zefiro Methane Corp. Implements A.I. Tools to Drive Commercial Expansion & Efficiency

March 14, 2025 17:30 ET  | Source: Zefiro Methane Corp FORT LAUDERDALE, Fla., March 14,…

5 hours ago

TREATMENT.COM AI INC. EXTENDS TERM OF MARKETING SERVICES PROVIDED BY I2I MARKETING GROUP

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE…

5 hours ago

Nokia Corporation: Repurchase of own shares on 14.03.2025

Nokia CorporationStock Exchange Release14 March 2025 at 22:30 EET Nokia Corporation: Repurchase of own shares…

5 hours ago

Inspired Entertainment and Welcome Break Extend Partnership

March 14, 2025 16:15 ET  | Source: Inspired Entertainment, Inc. NEW YORK, March 14, 2025…

5 hours ago

Celebrating 7 Years of BitMart: Key Takeaways from Our AMA Series

Mahe, Seychelles, March 14, 2025 (GLOBE NEWSWIRE) -- BitMart, a leading global cryptocurrency exchange, successfully…

5 hours ago